Predictive Model of Early Death of Resectable Pancreatic Ductal Adenocarcinoma After Curative Resection: A SEER-Based Study

Abstract

Objective This study aims to determine the factors that predict early death and establish a predictive model for early death by analyzing clinical characteristics of patients with resectable pancreatic ductal adenocarcinoma (R-PDAC) who die early after radical surgery. Materials and Methods This was a retrospective study of patients who underwent radical surgical resection for R-PDAC in the Surveillance, Epidemiology, and End Results (SEER) database. Patients with overall survival ≤ 12 months were assigned as early death group and above 1 year as the late death group. Univariate and multivariate logistic regression was conducted to identify factors significantly associated with early death. An early death predictive model was constructed based on the identified independent risk factors. Results A total of 9695 patients were analyzed, and the total incidence of early death was 30.72%. Multivariable analysis showed that factors significantly associated with early death included age at diagnosis, race, marital status, tumor location, tumor size, tumor grade, number of positive lymph nodes, number of examined lymph nodes, positive lymph node ratio, chemotherapy, and radiotherapy. The predictive model showed good discrimination with a C-index of 0.722 (95% confidence interval: 0.711-0.733) and convincing calibration. Conclusions We developed a predictive model that may be easily applied to patients with R-PDAC after radical resection to predict the chance of death within 1 year. For patients with high risk of early death, neoadjuvant therapy should be considered. Even after radical resection, more aggressive adjuvant chemotherapy (with or without combined radiotherapy) must be used to minimize the chance of early death.

Factors Associated With Early Recurrence in Ductal Adenocarcinoma of the Pancreas

“…To date, it is one of the few works with the largest amount of sample size that made cut-off points in the values of the predictors, establishing a prediction model with the aforementioned variables. [11] Analyzing the rest of the bibliography, we can see that this cut-off point for the tumor marker varies signi cantly between the different reference centers and there is no clear correlation in the cut-off value. The Japanese group of Imamura establishes a cutoff point of ca 19 − 9 of (> 52 U/mL) preoperative and (> 37 U/mL) postoperative.…”

Stem cell-like circulating tumor cells identified by Pep@MNP and their clinical significance in pancreatic cancer metastasis

“…Then we evaluated the accuracy to predict early recurrence rate for pancreatic cancer based on the HM-CTCs counts. Our team previously reported a multicenter retrospective study in which 9 months was the best threshold to distinguish early from late recurrence ( 53 ). We observed that the AUC of HM-CTCs in PB for distinguishing early recurrence was 0.787, and the accuracy significantly increased when we tested the AUC of PVB HM-CTCs (0.825).…”

Establishment of prediction model for mortality risk of pancreatic cancer: a retrospective study

“…In other words, predicting the oncological outcomes of this disease based on the prognostic factors plays a crucial role in increasing PC survival by detecting the factors contributing to worsening the patients’ outcomes at earlier stages [ 15 ]. More specifically, early prediction of the mortality risk of PC based on these factors can significantly increase PC survival by modifying these factors at earlier stages [ 16 , 17 ].…”